ReachRxResearch
Home
Research
Sign Up
Nucleic acid sensing pathways in kidney disease development
Back to Research Hub
  1. Home
  2. Research Hub
  3. Nucleic acid sensing pathways in kidney…

Nucleic acid sensing pathways in kidney disease development

Nature Reviews Nephrology·September 1
Urology & NephrologyPractice changingAcute Kidney InjuryAPOL1-Associated NephropathyAutosomal Dominant Polycystic Kidney DiseaseChronic Kidney DiseaseCrescentic GlomerulonephritisDiabetic Kidney DiseaseLupus NephritisRenal Cell CarcinomaNarrative ReviewCGAS–STING InhibitorGene TherapyJAK InhibitorMitochondrial ProtectorPrecision NanomedicineToll-Like Receptor ModulatorType I Interferon InhibitorMixedJakafiAnifrolumabBaricitinibChloroquineElamipretideHydroxychloroquineTofacitinib

Summary

View source

What was studied

This review evaluates the role of nucleic acid sensing pathways — chiefly cGAS–STING, AIM2, and endosomal Toll-like receptors (TLRs) — in kidney disease, covering both acute kidney injury (AKI) and chronic kidney disease (CKD) across glomerular and tubular compartments, and catalogues the therapeutic landscape targeting these pathways.

Key findings

Mislocalized self-nucleic acids (mitochondrial DNA, nuclear DNA fragments, reactivated endogenous retroelements) activate cGAS–STING, AIM2, and TLR pathways in podocytes, tubular epithelial cells, mesangial cells, and infiltrating immune cells, driving inflammation, fibrosis, and cell death across multiple kidney disease contexts. Therapeutic agents range from FDA-approved hydroxychloroquine (TLR7/9) to preclinical STING antagonists (H-151, C-176, LB244) and a Phase 2 cGAS inhibitor (VENT-03) in active cutaneous lupus.

Study limitations

This is a narrative review without systematic search methodology or meta-analysis, so conclusions reflect the authors' synthesis rather than pooled quantitative data. Most mechanistic evidence comes from mouse models, with limited human clinical trial data specifically in kidney endpoints. The therapeutic table includes agents at very early preclinical stages alongside approved drugs, making direct comparison of efficacy difficult.

Clinical implications

Clinicians managing lupus nephritis, diabetic kidney disease, APOL1-associated nephropathy, or AKI should be aware that cGAS–STING and TLR-driven sterile inflammation are active therapeutic targets, with several agents in Phase 2 trials (baricitinib, anifrolumab, VENT-03). Mitochondrial protection strategies (e.g., elamipretide) that limit mtDNA leakage represent an upstream approach to dampening innate immune activation in the kidney.

Caveats

  • Brand tag 'Jakafi' (ruxolitinib) was not explicitly named in the paper; it was omitted. The baricitinib brand (Olumiant) and anifrolumab brand (Saphnelo) were not listed in the paper either and were omitted accordingly.
  • The paper is a review article published in Nature Reviews Nephrology (2026); it synthesizes primary studies but does not present original trial data.
  • The Phase 3 anifrolumab lupus nephritis trial (NCT05138133) results were noted as not yet available at time of publication.
Show all 4
  • The 'practice_changing' impact flag reflects the breadth of emerging therapeutic targets reviewed, not a single pivotal trial result — most agents remain preclinical or in early-phase trials.

Related Questions

Explore related topics

Which cGAS-STING inhibitors are currently in clinical trials for kidney disease?How does mitochondrial DNA leakage drive inflammation in diabetic kidney disease?What is the role of APOL1 risk variants in activating innate immune pathways in the kidney?

Publication Details

Year
2026
Journal
Nature Reviews Nephrology
Source
View article
Keep scrolling
More content below.
Up Next